Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx mění a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. x č. 46/2008 Sb. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 1. října 2017 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx¹⁾.

X novým xxxxxx Xxxxxxx I xxxxxxxx souhlas Xxxxxxxxx Xxxxx republiky a xxxxxxxxx republiky podepsal xxxxxxx o xxxxxxx xxxx Přílohy X Xxxxxx republikou.

Nové xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2018. Xxx Českou xxxxxxxxx xxxxxxxxx nové xxxxx Xxxxxxx X x xxxxxxxx xxx 5. června 2019.

Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I xxxxxx xx 1. xxxxx 2017 x xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Anglické xxxxx xxxxxx xxxxx Xxxxxxx I x xxxx xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx současně.

SVĚTOVÁ

ANTIDOPINGOVÁ

AGENTURA

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX LÁTEK X XXXXX DOPINGU XXX XXX 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx text Seznamu xxxx xxxxxxxxx XXXX x xxxx publikován x xxxxxxxxxx a xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x francouzskou xxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx bude xxxxxx xx 1. xxxxx 2018 

XXXXXX XXXXXXXXXX XXXXX A XXXXX XXXXXXX XXX XXX 2018

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. ledna 2018

XXXXX A METODY XXXXXXXX STÁLE (PŘI SOUTĚŽI X XXXX XXXXXX)

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, S4.5 x S6(a) a Xxxxxxxxxx xxxxx M1, X2 x X3.

XXXXXXXX XXXXX

X0. NESCHVÁLENÉ LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta v xxxxxxxxxxxxx sekcích Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx použití jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx stadiu xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, syntetické xxxxx, xxxxx schválené xxxxx xxx veterinární použití), xx zakázána stále.

S1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx zakázány.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);

methylnortestosteron (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (methyltrienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

b. Xxxxxxxxx** XXX, pokud xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-dihydrotestosteron, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx metabolity x xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx na xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX, xxxx. xxxxxxx, XXX-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx a xxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.

Xxx xxxxx xxxxxxx xxxx sekce: * "exogenní" xx xxxxxxxx x xxxxx, kterou xxxx xxxxxxxx přirozeně xxxxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx x xxxxx látky x xxxxxxxx chemickou strukturou xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (EPO) x xxxxxxxxxx ovlivňující xxxxxxxxxxx, xxxxxx, ale xx x xxxxxxxx pouze xx xx:

1.1 Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx, např

darbepoetiny (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx založené xx XXX (XXX-Xx, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); EPO-mimetické xxxxxxxxxx x xxxxxx xxxxxxxxxx (xxxx. XXXX 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx prostředky xxxxxxx xxxxxxxxxxxxxx faktoru (HIF), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, např.

K-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; sotatercept.

1.5 Xxxxxxxx xxxxxxxxx opravného xxxxxxxxx. xxxx.

xxxxxx XXX; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (CG) x luteinizační xxxxxx (XX) x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxx, xxxxxxxxxx, gonadorelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x triptorelin, x xxxx.

2.2 Kortikotropiny a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx x xxxxxxxxxx xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx na ně:

fragmenty xxxxxxxxx hormonu, xxxx. XXX-9604 x hGH 176-191; hormon xxxxxxxxxx xxxxxxx hormon (XXXX) x jeho xxxxxxx, xxxx. XXX-1295, sermorelin x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. ghrelin x xxxxxxxx ghrelinu, xxxx. xxxxxxxxxx, ipamorelin x xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. alexamorelin, XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5, XXXX-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx a modulátory xxxxxxxxx xxxxxxx, včetně, xxx xx s xxxxxxxx pouze xx xx:

xxxxxxxxxxxxx růstové faktory (XXXx);

xxxxxxxxxxxx xxxxxxx faktor (XXX);

xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1) a xxxx xxxxxxx

xxxxxxxxxx růstové xxxxxxx (MGF);

růstový xxxxxx xxxxxxxx z krevních xxxxxxxx (XXXX);

xxxxxxxx- β4 x jeho xxxxxxxx, xxxx. TB-500;

vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX).

Xxxxx růstové xxxxxxx a xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x vaziva, xxxxxx xxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3. BETA2- AGONISTÉ

Všichni xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx s xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prokaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx v oddělených xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx za 24 hodin;
• inhalační salmeterol: xxxxxxxxx 200 mikrogramů xx 24 hodin.

Přítomnost xxxxxxxxxxx v moči x xxxxxxxxxxx vyšší xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx výsledek xxx xxxxxxxx xxxxxxxxxxxxx xxxxxx (v xxxxxxxx) xxxxx, xxx xxxx xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

Xxxxxxxx jsou následující xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x omezením xxxxx xx ně.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:

Raloxifen;

xxxxxxxxx;

xxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, xxx xx s xxxxxxxx xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX; x Agonisté Xxxxxxxxx xxxxx aktivovaného xxxxxxxxxxxxxx proliferátory (PPARδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) kyselina xxxxxx (GW1516, XX501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 meldonium;

5.4 trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx diuretika x xxxxxxxxx látky xxxx xxxxxxxx, stejně jako xxxxx xxxxx x xxxxxxxx chemickou strukturou x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, hydroxyethylškrobu a xxxxxxxxx); probenecid, xxx xx s xxxxxxxx xxxxx na xx.

• Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid); xxxxxxxxxx x vaptany (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxxx

Xxxxx jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) xx Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx tuto xxxxx xxxxx k té, xxxxx xxx byla xxxxxxx na xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X KRVÍ X XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx krvinek x jim podobných xxxxxxxx jakéhokoliv původu xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu x mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), ale ne x xxxxxxxx xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx kyslíkem xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. Xx zahrnuje xxxxxx a/nebo xxxxxx (xxxx. xxxxxxxxxx) moči, xxx xx x xxxxxxxx pouze na xx.

2. Nitrožilní xxxxxx x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx za 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních zákroků, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx diagnostických metod.

M3. XXXXXX XXXXXX

X důvodu xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Použití xxxxxxxx nukleových kyselin xxxx jejich xxxxxxx;

2. Xxxxxxx geneticky produkovaných xxxxxxxxx, vytvořených x xxxxxxxxxxx xxxxxxxx genomu x/xxxx x xxxxxxxxxxxx xxxx xxxxxxxxxxxx regulaci xxxxxx exprese.

3. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx kategorií X0 xx X5 x X1 xx M3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:

ZAKÁZANÉ LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx stimulancia:

Adrafinil;

amfepramon;

amfetamin;

amfetaminil;

amifenazol;

benfluorex;

benzylpiperazin;

bromantan;

fendimetrazin;

fenetylin;

fenfluramin;

fenkamin;

fenproporex;

fentermin;

fonturacetam /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx výslovně uvedeno x tomto odstavci, xx Xxxxxxxxxxx látkou.

(b) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (ale xx x xxxxxxxx xxxxx na xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon a xxxx analoga (např. xxxxxxxx, methedron x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (metylhexanamin);

niketamid;

norfenefrin;

oktopamin;

oxilofrin (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další xxxxx x podobnou chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx místního/očního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx rok 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x synefrin: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2018 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Katin: je xxxxxxxx xxxxx xxx xxxxxxxxxxx vyšší xxx 5 mikrogramů x 1 xx moči.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší xxx 10 xxxxxxxxxx x 1 ml xxxx.

**** Xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxx xxx lokálním xxxxxx, např. nosní, xxxx aplikace nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx koncentrace x xxxx xx xxxxx než 150 xxxxxxxxxx na xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx narkotika jsou xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx xxxxxxxxxxx xxxx zakázané:

• Přírodní xxxxxxxxxxx, xxxx. xxxxx, xxxxxx x marihuana.

• Syntetické xxxxxxxxxxx, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x ostatní kanabimimetika.

Kromě: xxxxxxxxxxxx

X9. GLUKOKORTIKOIDY

Všechny glukokortikoidy xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.

Xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, a kde xx xx xxxxxxxx x Mimo xxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (všechny xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (FIS) - xxxxx xx lyžích x xxxxxxxxxxx lyžování-skoky x U-rampa, x xxxxxxxxx X-xxxxx a "xxx xxx"

• Xxxxxxxx sporty (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx x xxxxxxxxx xxxx bez xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx xxxx xxx xxxxxxx, xxxx immersion, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, střelba xxxxxxxx xx terč x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, IPC)*

• Šipky (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx na xx.

Xxxxxxxxx

Xxxxxx předpis č. 36/2019 Sb. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. x xxxxxxxxx xx 22.8.2023.

Xxxxx jednotlivých xxxxxxxx norem jiných xxxxxxxx předpisů v xxxxxxxx xxxx aktualizováno, xxxxx se jich xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx a s xxxxxxxxx do českého xxxxxx pod č. 58/2007 Sb. m. s.

Nové xxxxx překladu Xxxxxx xx českého jazyka xxxx xxxxxxxxx pod č. 46/2008 Sb. m. s.